Boston Scientific (BSX) Beats Q4 Earnings and Revenue Estimates

Core Viewpoint - Boston Scientific reported quarterly earnings of $0.8 per share, exceeding the Zacks Consensus Estimate of $0.78 per share, and showing an increase from $0.7 per share a year ago, indicating a positive earnings surprise of +2.96% [1] Financial Performance - The company achieved revenues of $5.29 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 0.39%, and up from $4.56 billion year-over-year [2] - Over the last four quarters, Boston Scientific has consistently exceeded consensus EPS estimates and revenue estimates [2] Stock Performance - Boston Scientific shares have declined approximately 3.9% since the beginning of the year, while the S&P 500 has gained 1.1% [3] - The stock's immediate price movement will largely depend on management's commentary during the earnings call [3] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.79, with expected revenues of $5.2 billion, and for the current fiscal year, the EPS estimate is $3.45 on revenues of $22.32 billion [7] - The estimate revisions trend for Boston Scientific was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical - Products industry, to which Boston Scientific belongs, is currently ranked in the bottom 34% of over 250 Zacks industries, suggesting potential challenges ahead [8] - The performance of Boston Scientific's stock may be influenced by the overall outlook for the industry [8]